** Shares of AIM Vaccine Co Ltd 6660.HK jump as much as 13.2% to HK$6.35; on course for biggest one-day gain since October 17, 2024
** Stock on track for the second session of gain
** AIM says U.S. Food and Drug Administration (FDA) has approved its application for clinical trial of mRNA respiratory syncytial virus vaccines
** The Chinese mRNA vaccine products developer says it is U.S. FDA's first approval for the company's products, marking a "significant progress" for its global strategy
** Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI both add 0.1%, healthcare index .HSCIH gains 0.2%
** Stock up 1.5% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.